FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293037176> ?p ?o ?g. }

• W4293037176 abstract "Publications suggest immunomodulation co-therapy improves responder rates in uncontrolled/refractory gout patients undergoing pegloticase treatment. The MIRROR open-label trial showed a 6-month pegloticase + methotrexate co-therapy responder rate of 79%, compared to an established 42% pegloticase monotherapy responder rate. Longer-term efficacy/safety data are presented here.Uncontrolled gout patients (serum urate [SU] ≥ 6 mg/dL and SU ≥ 6 mg/dL despite urate-lowering therapy [ULT], ULT intolerance, or functionally-limiting tophi) were included. Patients with immunocompromised status, G6PD deficiency, severe kidney disease, or methotrexate contraindication were excluded. Oral methotrexate (15 mg/week) and folic acid (1 mg/day) were administered 4 weeks before and during pegloticase therapy. Twelve-month responder rate (SU < 6 mg/dL for ≥ 80% during month 12), 52-week change from baseline in SU, and extended safety were examined. Efficacy analyses were performed for patients receiving ≥ 1 pegloticase infusion. Pharmacokinetics (PK)/anti-drug antibodies (ADAs) were examined and related to efficacy/safety findings.Fourteen patients were included (all male, 49.3 ± 8.7 years, 13.8 ± 7.4-year gout history, pre-therapy SU 9.2 ± 2.5 mg/dL). Three patients were non-responders and discontinued study treatment before 24 weeks, one patient exited the study per protocol at 24 weeks (enrolled prior to treatment extension amendment), and 10 remained in the study through week 52. Of the 10, 8 completed 52 weeks of pegloticase + methotrexate and were 12-month responders. The remaining two discontinued pegloticase + methotrexate at week 24 (met treatment goals) and stayed in the study under observation (allopurinol prescribed at physicians' discretion); one remained a responder at 12 months. At 52 weeks, change from baseline in SU was - 8.2 ± 4.1 mg/dL (SU 1.1 ± 2.4 mg/dL, n = 10). Gout flares were common early in treatment but progressively decreased while on therapy (weeks 1-12, 13/14 [92.9%]; weeks 36-52, 2/8 [25.0%]). One patient recovered from sepsis (serious AE). Two non-responders developed high ADA titers; fewer patients had trough concentrations (Cmin) below the quantitation limit (BQL), and the median Cmin was higher (1.03 µg/mL vs. BQL) than pegloticase monotherapy trials.Pegloticase + methotrexate co-therapy was well-tolerated over 12 months, with sustained SU lowering, progressive gout flare reduction, and no new safety concerns. Antibody/PK findings suggest methotrexate attenuates ADA formation, coincident with higher treatment response rates.ClinicalTrials.gov, NCT03635957 . Registered on 17 August 2018." @default.
• W4293037176 created "2022-08-25" @default.
• W4293037176 creator A5009441700 @default.
• W4293037176 creator A5030288625 @default.
• W4293037176 creator A5038373277 @default.
• W4293037176 creator A5047117557 @default.
• W4293037176 creator A5048967469 @default.
• W4293037176 creator A5050753911 @default.
• W4293037176 creator A5061747057 @default.
• W4293037176 creator A5061912155 @default.
• W4293037176 creator A5062601886 @default.
• W4293037176 creator A5066263281 @default.
• W4293037176 creator A5069421572 @default.
• W4293037176 creator A5071817691 @default.
• W4293037176 creator A5074500809 @default.
• W4293037176 creator A5088197516 @default.
• W4293037176 date "2022-08-25" @default.
• W4293037176 modified "2023-10-06" @default.
• W4293037176 title "A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study" @default.
• W4293037176 cites W1561987315 @default.
• W4293037176 cites W1741764841 @default.
• W4293037176 cites W1830490643 @default.
• W4293037176 cites W1860576659 @default.
• W4293037176 cites W1965212373 @default.
• W4293037176 cites W1978895759 @default.
• W4293037176 cites W1991633185 @default.
• W4293037176 cites W1996472975 @default.
• W4293037176 cites W2002849282 @default.
• W4293037176 cites W2006532575 @default.
• W4293037176 cites W2014015529 @default.
• W4293037176 cites W2048359032 @default.
• W4293037176 cites W2049505234 @default.
• W4293037176 cites W2060100993 @default.
• W4293037176 cites W2067874068 @default.
• W4293037176 cites W2081241683 @default.
• W4293037176 cites W2093707453 @default.
• W4293037176 cites W2102831957 @default.
• W4293037176 cites W2115030795 @default.
• W4293037176 cites W2119537052 @default.
• W4293037176 cites W2126158243 @default.
• W4293037176 cites W2131885572 @default.
• W4293037176 cites W2150224561 @default.
• W4293037176 cites W2155024437 @default.
• W4293037176 cites W2165692098 @default.
• W4293037176 cites W2167491049 @default.
• W4293037176 cites W2205862613 @default.
• W4293037176 cites W2326355551 @default.
• W4293037176 cites W2335302945 @default.
• W4293037176 cites W2365692845 @default.
• W4293037176 cites W2769532298 @default.
• W4293037176 cites W2921799458 @default.
• W4293037176 cites W3023256684 @default.
• W4293037176 cites W3034847577 @default.
• W4293037176 cites W3044515532 @default.
• W4293037176 cites W3087595653 @default.
• W4293037176 cites W3104690239 @default.
• W4293037176 cites W3139148124 @default.
• W4293037176 cites W4225260803 @default.
• W4293037176 cites W4226484168 @default.
• W4293037176 cites W4229537562 @default.
• W4293037176 doi "https://doi.org/10.1186/s13075-022-02865-z" @default.
• W4293037176 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36008814" @default.
• W4293037176 hasPublicationYear "2022" @default.
• W4293037176 type Work @default.
• W4293037176 citedByCount "3" @default.
• W4293037176 countsByYear W42930371762022 @default.
• W4293037176 countsByYear W42930371762023 @default.
• W4293037176 crossrefType "journal-article" @default.
• W4293037176 hasAuthorship W4293037176A5009441700 @default.
• W4293037176 hasAuthorship W4293037176A5030288625 @default.
• W4293037176 hasAuthorship W4293037176A5038373277 @default.
• W4293037176 hasAuthorship W4293037176A5047117557 @default.
• W4293037176 hasAuthorship W4293037176A5048967469 @default.
• W4293037176 hasAuthorship W4293037176A5050753911 @default.
• W4293037176 hasAuthorship W4293037176A5061747057 @default.
• W4293037176 hasAuthorship W4293037176A5061912155 @default.
• W4293037176 hasAuthorship W4293037176A5062601886 @default.
• W4293037176 hasAuthorship W4293037176A5066263281 @default.
• W4293037176 hasAuthorship W4293037176A5069421572 @default.
• W4293037176 hasAuthorship W4293037176A5071817691 @default.
• W4293037176 hasAuthorship W4293037176A5074500809 @default.
• W4293037176 hasAuthorship W4293037176A5088197516 @default.
• W4293037176 hasBestOaLocation W42930371761 @default.
• W4293037176 hasConcept C126322002 @default.
• W4293037176 hasConcept C141071460 @default.
• W4293037176 hasConcept C197934379 @default.
• W4293037176 hasConcept C198451711 @default.
• W4293037176 hasConcept C2780402116 @default.
• W4293037176 hasConcept C2781059491 @default.
• W4293037176 hasConcept C71924100 @default.
• W4293037176 hasConceptScore W4293037176C126322002 @default.
• W4293037176 hasConceptScore W4293037176C141071460 @default.
• W4293037176 hasConceptScore W4293037176C197934379 @default.
• W4293037176 hasConceptScore W4293037176C198451711 @default.
• W4293037176 hasConceptScore W4293037176C2780402116 @default.
• W4293037176 hasConceptScore W4293037176C2781059491 @default.
• W4293037176 hasConceptScore W4293037176C71924100 @default.
• W4293037176 hasFunder F4320319146 @default.
• W4293037176 hasIssue "1" @default.
• W4293037176 hasLocation W42930371761 @default.

• next